News

Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
The Manila Times3d

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...
The Bakersfield Californian3d

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...
TipRanks on MSN3d

Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...
pharmaphorum4d

MASH Drug Development Summit

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to ...

DelveInsight Business Research, LLP: IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver ...

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and ...